Literature DB >> 28719465

Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression.

Bin Xu1, Esther Drill, Allen Ho, Alan Ho, Lara Dunn, Carlos Nicolas Prieto-Granada, Timothy Chan, Ian Ganly, Ronald Ghossein, Nora Katabi.   

Abstract

Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy and it has a high rate of recurrences and a poor long-term prognosis. Our aim was to assess the prognostic factors in ACC and study MYB-NFIB fusion and MYB protein expression in a large retrospective cohort of 135 patients with a median follow-up of 6.3 years. The 5- and 10-year local recurrence-free survival (RFS) rate of 94% and 78%, 5- and 10-year distant metastasis survival rate of 77% and 58%, and 5- and 10-year RFS of 66% and 44%. The following features were identified as adverse prognostic factors of RFS on univariate analysis: large tumor size, solid growth pattern, increased mitoses, positive margin, American Joint Committee on Cancer clinical staging, high-grade transformation, vascular invasion, nuclear atypia, open chromatin, prominent nucleoli, and tumor necrosis. However, on multivariate analysis, only increased mitoses (≥5/10 high-power fields), any solid growth pattern, and advanced American Joint Committee on Cancer TNM staging were independent adverse predictors for RFS. MYB immunoexpression and MYB-NFIB translocation were common findings in ACC, occurring in 72% and 59% of the tested ACCs, respectively. The sensitivity and specificity of MYB immunohistochemistry in detecting MYB-NFIB fusion was relatively low at 78% sensitivity and 50% specificity. The high prevalence of alterations leading to high expression of the MYB transcription factor family suggests that targeted approaches developed to suppress the expression of these oncogenic transcription factors and/or the transcriptional activity of these proteins would be a rational therapeutic approach to investigate in ACC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28719465      PMCID: PMC5597477          DOI: 10.1097/PAS.0000000000000918

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  37 in total

1.  Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA).

Authors:  Kristine Bjørndal; Annelise Krogdahl; Marianne H Therkildsen; Birgitte Charabi; Claus A Kristensen; Elo Andersen; Sten Schytte; Hanne Primdahl; Jørgen Johansen; Henrik B Pedersen; Lisbeth J Andersen; Christian Godballe
Journal:  Oral Oncol       Date:  2015-10-21       Impact factor: 5.337

Review 2.  Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review.

Authors:  Carlos Suárez; Leon Barnes; Carl E Silver; Juan P Rodrigo; Jatin P Shah; Asterios Triantafyllou; Alessandra Rinaldo; Antonio Cardesa; Karen T Pitman; Luiz P Kowalski; K Thomas Robbins; Henrik Hellquist; Jesus E Medina; Remco de Bree; Robert P Takes; Andrés Coca-Pelaz; Patrick J Bradley; Douglas R Gnepp; Afshin Teymoortash; Primož Strojan; William M Mendenhall; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Marc Hamoir; Pieter J Slootweg; Vincent Vander Poorten; Michelle D Williams; Bruce M Wenig; Alena Skálová; Alfio Ferlito
Journal:  Auris Nasus Larynx       Date:  2016-03-24       Impact factor: 1.863

3.  Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme.

Authors:  Stijn van Weert; Isaäc van der Waal; Birgit I Witte; C René Leemans; Elisabeth Bloemena
Journal:  Oral Oncol       Date:  2014-10-28       Impact factor: 5.337

4.  Adenoid cystic carcinoma of head and neck: clinical predictors of outcome from a Canadian centre.

Authors:  J J Ko; J E Siever; D Hao; R Simpson; H Y Lau
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

5.  Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.

Authors:  Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

6.  Head and neck adenoid cystic carcinoma: A prospective multicenter REFCOR study of 95 cases.

Authors:  M Meyers; B Granger; P Herman; F Janot; R Garrel; N Fakhry; G Poissonnet; B Baujat
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2015-10-20       Impact factor: 2.080

Review 7.  MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.

Authors:  Renata Ferrarotto; John V Heymach; Bonnie S Glisson
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

8.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

9.  The mutational landscape of adenoid cystic carcinoma.

Authors:  Allen S Ho; Kasthuri Kannan; David M Roy; Luc G T Morris; Ian Ganly; Nora Katabi; Deepa Ramaswami; Logan A Walsh; Stephanie Eng; Jason T Huse; Jianan Zhang; Igor Dolgalev; Kety Huberman; Adriana Heguy; Agnes Viale; Marija Drobnjak; Margaret A Leversha; Christine E Rice; Bhuvanesh Singh; N Gopalakrishna Iyer; C Rene Leemans; Elisabeth Bloemena; Robert L Ferris; Raja R Seethala; Benjamin E Gross; Yupu Liang; Rileen Sinha; Luke Peng; Benjamin J Raphael; Sevin Turcan; Yongxing Gong; Nikolaus Schultz; Seungwon Kim; Simion Chiosea; Jatin P Shah; Chris Sander; William Lee; Timothy A Chan
Journal:  Nat Genet       Date:  2013-05-19       Impact factor: 38.330

10.  An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.

Authors:  Yotam Drier; Matthew J Cotton; Kaylyn E Williamson; Shawn M Gillespie; Russell J H Ryan; Michael J Kluk; Christopher D Carey; Scott J Rodig; Lynette M Sholl; Amir H Afrogheh; William C Faquin; Lurdes Queimado; Jun Qi; Michael J Wick; Adel K El-Naggar; James E Bradner; Christopher A Moskaluk; Jon C Aster; Birgit Knoechel; Bradley E Bernstein
Journal:  Nat Genet       Date:  2016-02-01       Impact factor: 38.330

View more
  20 in total

1.  SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.

Authors:  Brian D Adkins; Ariana Geromes; Lily Y Zhang; Rebecca Chernock; Katherine Kimmelshue; James Lewis; Kim Ely
Journal:  Head Neck Pathol       Date:  2019-06-20

2.  MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms.

Authors:  Justin A Bishop; William H Westra
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

3.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Authors:  Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

4.  Assessment of CTNNB1 gene mutations and β-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas.

Authors:  Roberta Barroso Cavalcante; Cassiano Francisco Weege Nonaka; Hellen Bandeira de Pontes Santos; Silvia Helena Barem Rabenhorst; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  Virchows Arch       Date:  2018-03-26       Impact factor: 4.064

5.  Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.

Authors:  Julie Massé; Caroline Truntzer; Romain Boidot; Emmanuel Khalifa; Gaëlle Pérot; Valérie Velasco; Laétitia Mayeur; Claire Billerey-Larmonier; Larry Blanchard; Hélène Charitansky; Isabelle Soubeyran; Richard Iggo; Laurent Arnould; Gaëtan MacGrogan
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

6.  Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.

Authors:  Bao Sun; Yu Wang; Jingjing Sun; Chunye Zhang; Ronghui Xia; Shengming Xu; Shuyang Sun; Jiang Li
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

7.  Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.

Authors:  Petr Šteiner; Simon Andreasen; Petr Grossmann; Lukáš Hauer; Tomáš Vaněček; Markéta Miesbauerová; Thalita Santana; Katalin Kiss; David Slouka; Alena Skálová
Journal:  Virchows Arch       Date:  2018-04-04       Impact factor: 4.064

Review 8.  Polymorphous Adenocarcinoma.

Authors:  Nora Katabi; Bin Xu
Journal:  Surg Pathol Clin       Date:  2021-01-05

9.  Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts.

Authors:  Bin Xu; Ronald Ghossein; Alan Ho; Kartik Viswanathan; Anjanie Khimraj; Maelle Saliba; Jennifer R Cracchiolo; Nora Katabi
Journal:  Head Neck       Date:  2021-04-24       Impact factor: 3.821

10.  MYB-NFIB Translocation by FISH in Adenoid Cystic Carcinoma of the Head and Neck in Nigerian Patients: A Preliminary Report.

Authors:  Adepitan A Owosho; Olufunlola M Adesina; Oluwole Odujoko; Olujide O Soyele; Akinwumi Komolafe; Robert Bauer; Kallie Holte; Kurt F Summersgill
Journal:  Head Neck Pathol       Date:  2020-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.